Raymond Plodkowski is an Endocrinology/Metabolic physician affiliated with University of California San Diego. OpenAlex indexes 32 publications with 4,206 citations (h-index 13); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12395 El Camino Real
Suite 317
San Diego, CA 921303082
Telephone
858-794-1250Registry record last updated 20 Sept 2012.
Clinical trials
- Weight Loss and Abdominal Fat Responses to Different Diet Compositions
Sponsor: University of Nevada, Las Vegas
- Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
Sponsor: Orexigen Therapeutics, Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year202578 payments$61,039openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year202556 payments$48,409openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202518 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
78.2%Biguanide (metformin)43.4%Metformin Hcl Er70%Metformin Hcl30%Part D≥182 patientsGLP-1 receptor agonist27.1%Ozempic73%Mounjaro18%Wegovy6%Trulicity3%Part D<11 patients+ 5 more classes in this area
Hormonal (systemic)
9.4%l-Thyroxine7.9%Levothyroxine Sodium86%Synthroid14%Part D<11 patientsl-Triiodothyronine1.5%Liothyronine Sodium100%Part D<11 patientsNervous system
8.3%Aminoketone4.4%Bupropion Xl67%Bupropion Hcl Sr33%Part D<11 patientsOpioid Antagonist2.5%Naltrexone Hcl100%Part D≥13 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy
International Journal of Obesity
2016 - Obesity Management: Clinical Review and Update of the Pharmacologic Treatment Options.
PubMed
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Jay Giedd, MD
University of California San Diego
Robert Weinreb, MD
University of California San Diego
Dilip Jeste, MD
University of California San Diego
Igor Grant, MD
University of California San Diego
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”